Grapiprant

Drug Profile

Grapiprant

Alternative Names: 423; AAT-007; CJ-023; CJ-023,423; CJ-23423; MR-10A7; RQ-00000007; RQ-7

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer AskAt; Maruishi Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
  • Mechanism of Action Epidermal growth factor inhibitors; Interleukin 23 inhibitors; Interleukin 6 inhibitors; Interleukin-17 inhibitors; Prostaglandin E EP4 receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Inflammatory pain
  • Phase I Acute pain; Autoimmune disorders; Hypersensitivity; Inflammation
  • Preclinical Cancer; Cancer pain; Postoperative pain

Most Recent Events

  • 01 Jan 2016 Grapiprant licensed to RMX Pharmaceutical Technology in China
  • 04 Sep 2015 University of Maryland plans a phase II trial for Solid tumours (Late-stage disease) in USA (NCT02538432)
  • 24 Jun 2015 Grapiprant is still in phase II development for Inflammatory pain in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top